Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends

Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to buy heading into 2026. On December 5, Kerry Holford, an analyst at Berenberg Bank, reaffirmed the ‘Buy’ rating on Novo Nordisk A/S (NYSE:NVO) and kept the price target at $62, suggesting an upside potential of about 29%.

Earlier on December 3, Reuters sources revealed that Novo Nordisk A/S (NYSE:NVO) will make its blockbuster diabetes drug Ozempic available in the Indian market this month. This launch is in line with the company’s commitment to strengthen its position in the “world’s most populous nation,” they added. With the second-highest number of people with type 2 diabetes and rising obesity rates, India is a fast-growing weight-loss solution space, which is anticipated to hit nearly $150 billion per year by the end of the decade.

Overall, Novo Nordisk A/S (NYSE:NVO) is assigned ‘Buy’ or equivalent ratings from almost 60% of the analysts, with a median price target of $62.01. This implies an upside potential of 29.57% from the current price of $47.86.

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based company that specializes in pharmaceutical products. Founded in 1923, the giant operates through two segments: Diabetes and Obesity Care, and Rare Disease.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.